scholarly journals Prognostic Value of CD9 in Solid Tumor: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Ping Zeng ◽  
Meng Si ◽  
Rui-xia Sun ◽  
Xu Cheng ◽  
Xiao-yang Li ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Solid Tumors ◽  
Neck Cancer ◽  
Solid Tumor ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
Human Solid Tumors ◽  
Low Expression

Numerous clinical studies investigated how low expression of CD9 predicts poor prognosis of solid tumor. However, the results were inconclusive. This present meta-analysis was therefore performed to determine the prognostic value of CD9 expression in solid tumors. In this meta-analysis, 25 studies involving 5,555 participants were included; the result showed strong significant associations between declined expression of CD9 and all endpoints: overall survival (OS) (hazard ratio (HR) = 1.88, 95% CI = 1.45–2.43, p < 0.000) and time to progression (TTP) (HR = 2.0, 95% CI = 1.38–2.88, p < 0.000). The subgroup analysis was also performed, which revealed that the associations between CD9 downregulated expression related to poor OS in lung cancer and head and neck cancer. Also, low expression of CD9 was significantly connected with poor TTP in patients with head and neck cancer. The adverse prognostic impact of decreased expression of CD9 was observed in patients of different ethnicities. In conclusion, these results showed that declined expression of CD9 was associated with poor survival in human solid tumors. CD9 may be a valuable prognostic predictive biomarker and a potential therapeutic target in human solid tumors.

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data

Oral Oncology ◽  
2017 ◽  
Vol 74 ◽  
pp. 68-76 ◽  
Author(s):  
Petr Szturz ◽  
Marie Budíková ◽  
Jan B. Vermorken ◽  
Ivana Horová ◽  
Břetislav Gál ◽  
...  
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Aggregate Data

scholarly journals Association between PD-L1 expression and head and neck cancer prognosis: a meta-analysis

2019 ◽  
Author(s):  
Zhisen Shen ◽  
Linrong Wu ◽  
Xianlei Cai ◽  
Dong Ye ◽  
Gangjun Zhao
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Meta Analysis ◽  
Head And Neck Tumors ◽  
Cancer Prognosis ◽  
Cochrane Library ◽  
Prognostic Impact ◽  
Poor Prognostic Factor ◽  
Neck Tumors

Abstract Background: Programmed cell death ligand 1（PD-L1) plays an important role in tumor cell immune escape, and it has been extensively studied in head and neck cancer. However, its prognostic impact on patients with head and neck cancer remains controversial, so we sought to investigate this issue through a comprehensive meta-analysis. Methods: To assess the significance of PD-L1 on the survival of patients with head and neck cancer, we collected articles reported in PubMed, EMBASE, and Cochrane Library, until January 31, 2019. We also used the Newcastle Ottawa Scale (NOS) for literature quality evaluation. Results: The study included a total of 4551 patients affected by 6 different types of head and neck cancer reported in 26 articles. Our study found that the association between the expression of PD-L1 and the prognosis of head and neck tumors was highly heterogeneous (P < 0.00001, I2 = 80.0%); therefore, the random effects model was applied to combine the effect sizes. Based on the combined hazard ratios (HR)of 1.15 (95% CI: 0.88 to 1.50, P = 0.32), the expression of PD-L1 in head and neck tumors may not be a factor associated with poor prognosis. Conclusions: Our results suggest that PD-L1 expression cannot predict the overall survival of patients with oral, nasopharyngeal, or esophageal cancer. Through subgroup analysis, we found that the expression of PD-L1 may be a poor prognostic factor for some head and neck cancers.

scholarly journals Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis

Aging ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 501-522 ◽  
Author(s):  
Yi-Qun Jia ◽  
Bo Yang ◽  
Li-Ling Wen ◽  
Wen-Xin Mu ◽  
Zhi Wang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Immune Checkpoint ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Immune Checkpoint Molecules

scholarly journals Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis

PLoS ONE ◽  
2021 ◽  
Vol 16 (10) ◽  
pp. e0259288
Author(s):  
Yukinori Takenaka ◽  
Norihiko Takemoto ◽  
Ryohei Oya ◽  
Hidenori Inohara
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Modality ◽  
Meta Analysis ◽  
Prognostic Impact ◽  
Poor Prognostic Factor ◽  
Radiotherapy Group ◽  
Surgery Group ◽  
The Impact

Background The objective of this study was to compare the prognostic impact of sarcopenia in patients with head and neck cancer (HNC) treated with surgery or radiation. Methods We systematically searched electronic databases to identify articles reporting the impact of sarcopenia on the prognosis of patients with HNC. Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) were extracted and pooled. HR according to treatment modality were estimated using random-effects models. Statistical analyses were carried out using the Comprehensive Meta-Analysis software. Results In total, 18 studies enrolling 3,233 patients were included. Sarcopenia was associated with poor OS in both surgery and radiotherapy groups (hazard ratio [HR] 2.50, 95% confidence interval [CI] 1.95–3.21; HR 1.63, 95% CI 1.40–1.90, respectively). The HR was significantly higher in the surgery group than in the radiotherapy group (p = 0.004), with similar results obtained for DFS (HR 2.59, 95% CI 1.56–4.31; HR 1.56, 95% CI 1.24–1.97 for the surgery and radiotherapy groups, respectively) and DSS (HR 2.96, 95% CI 0.73–11.95; HR 2.67, 95% CI 1.51–4.73 for the surgery and RT groups, respectively). Conclusions Sarcopenia was a poor prognostic factor for HNC, regardless of the treatment modality. However, the adverse effects of sarcopenia on survival were more prominent in the surgery group than in the radiotherapy group. Sarcopenia assessment is required for appropriate treatment decision-making.

Sign in / Sign up

Export Citation Format

Share Document